Melanoma PBMC

About Melanoma PBMC

Melanoma PBMC for Tumour Immunology Research

Melanoma Human PBMC products are cryopreserved peripheral blood mononuclear cells from IRB-consented donors with a clinically confirmed melanoma diagnosis. Cells are processed within 24 hours of collection and stored in CryoStor® CS10, supporting immuno-oncology, checkpoint biology, and cell therapy research.

Melanoma Tumour Immunology and Why PBMC

Melanoma is a malignancy of melanocytes and a neoplastic, not autoimmune, disease. It has become the reference indication for cancer immunotherapy, which makes patient-derived circulating immune cells especially valuable:

• High tumour mutational burden. Ultraviolet-induced DNA damage produces a characteristic mutational signature and a large neoantigen pool, underpinning melanoma’s immunogenicity
• Defined oncogenic drivers include activating BRAF mutations, NRAS mutations, and NF1 loss, which stratify patients for targeted therapy and interact with immune escape mechanisms
• Checkpoint blockade is standard of care in advanced disease, targeting PD-1, PD-L1, CTLA-4, and LAG-3; peripheral immune state is widely studied as a correlate of response and of immune-related adverse events
• T-cell exhaustion and differentiation state — PD-1, TIM-3, LAG-3, and TOX expression across circulating CD8+ subsets — is a central readout in melanoma immunology
• Defined tumour antigens such as MART-1, gp100, tyrosinase, and NY-ESO-1 make antigen-specific T-cell detection and expansion tractable from peripheral blood
• Why PBMC: the cryopreserved format supports immunophenotyping, TCR repertoire sequencing, antigen-specific expansion, cytotoxicity assays, and cell therapy process development from a single genotyped donor

Donor Stratification Available

• Stage at collection, including localised, regional nodal, and metastatic disease
• BRAF mutation status where clinically tested
• Treatment status: treatment-naive, post-resection, on checkpoint inhibitor therapy, or on BRAF/MEK-targeted therapy
• Documented treatment response or progression status
• Primary site and histological subtype where available
• Age, sex assigned at birth, race/ethnicity, and Fitzpatrick skin type
• Matched healthy controls available

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed melanoma donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified melanoma diagnosis
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies and infectious disease history
• Staging, treatment history, and additional melanoma-specific data available upon request

Applications

• Immunophenotyping of T-cell, NK, and myeloid populations in melanoma
• T-cell exhaustion and checkpoint receptor expression profiling
• Antigen-specific T-cell detection and expansion against melanoma antigens
• Ex vivo checkpoint blockade pharmacology and functional cytotoxicity assays
• T-cell receptor repertoire sequencing and clonal tracking
• Cell therapy and engineered T-cell process development from patient material
• Single-cell RNA sequencing and multi-omic immune profiling
• Biomarker discovery for immunotherapy response and toxicity

Other Melanoma Specimen Types

• Melanoma Leukopak — apheresis-derived, for high cell-number requirements
• Melanoma Serum and Melanoma Plasma — for circulating protein, cytokine, and cell-free DNA work
• Melanoma Whole Blood — fresh, for same-day assays and genotyping
• Skin Cancer PBMC — broader cutaneous oncology cohort including keratinocyte carcinomas
• Solid Tumor Cancer PBMC — for pan-tumour comparisons

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11-compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Melanoma PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. For healthy-donor controls and the full specimen range, see our human PBMCs collection.